Sep 15, 2026 · 7 min · 8 segments
It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval…
This was a thin week.
Only one paper cleared our bar for top-tier journals, and it's a review article rather than fresh trial data.
But it's a good one, so let's spend some time with it.
Published in the European Journal of Endocrinology, a team led by Gerardo Mazziotti takes on a problem that doesn't get talked about enough, the bone and joint disease that shows up in acromegaly patients.
Traditionally, doctors have treated this as two separate issues, bone fragility on one hand and joint disease or arthropathy on the other.
This review argues that's the wrong way to think about it.
The authors make the case that bone, joints, muscle, and even overall body composition all remodel together as one connected process in response to years of excess growth hormone exposure.
And here's the part that really matters for patients.
This musculoskeletal damage often doesn't go away even after the underlying hormone problem is successfully treated.
So a patient can have their growth hormone levels perfectly controlled and still be dealing with fractures, joint pain, and muscle problems years later.
The authors also point out a real gap in how doctors currently screen for this.
Standard bone density scans, the kind used for osteoporosis, don't fully capture the fracture risk these patients actually face.
Their bottom line is that acromegaly care needs to shift toward long-term whole-body musculoskeletal surveillance, not just hormone monitoring, and they lay out a framework for how clinicians might start doing that.
It's a conceptual paper, not a clinical trial, but it's the kind of thing that could quietly reshape how endocrinologists follow these patients for years after treatment.
And to be transparent about the thin week, no other acromegaly papers made the cut this time.
That happens sometimes, and we'd rather tell you honestly than pad the segment.
This was a thin week.
Only one paper cleared our bar for top-tier journals, and it's a review article rather than fresh trial data.
But it's a good one, so let's spend some time with it.
Published in the European Journal of Endocrinology, a team led by Gerardo Mazziotti takes on a problem that doesn't get talked about enough, the bone and joint disease that shows up in acromegaly patients.
Traditionally, doctors have treated this as two separate issues, bone fragility on one hand and joint disease or arthropathy on the other.
This review argues that's the wrong way to think about it.
The authors make the case that bone, joints, muscle, and even overall body composition all remodel together as one connected process in response to years of excess growth hormone exposure.
And here's the part that really matters for patients.
This musculoskeletal damage often doesn't go away even after the underlying hormone problem is successfully treated.
So a patient can have their growth hormone levels perfectly controlled and still be dealing with fractures, joint pain, and muscle problems years later.
The authors also point out a real gap in how doctors currently screen for this.
Standard bone density scans, the kind used for osteoporosis, don't fully capture the fracture risk these patients actually face.
Their bottom line is that acromegaly care needs to shift toward long-term whole-body musculoskeletal surveillance, not just hormone monitoring, and they lay out a framework for how clinicians might start doing that.
It's a conceptual paper, not a clinical trial, but it's the kind of thing that could quietly reshape how endocrinologists follow these patients for years after treatment.
And to be transparent about the thin week, no other acromegaly papers made the cut this time.
That happens sometimes, and we'd rather tell you honestly than pad the segment.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.